Boston Scientific_ Reminder why it's the BOS
BOF&麦肯锡·2025-02-09 04:54
February 5, 2025 12:26 PM GMT Boston Scientific | North America Reminder why it's the BOS Reaction to earnings Unchanged Meaningful upside Modest revision higher Impact to our investment thesis Financial results versus consensus Impact to next 12-month consensus EPS Exceptional Q4 finish at 19.5% organic vs. buyside expectations of c. 18% we believe. Broad based strength across divisions with notable improvement in Neuromod. 2025 guide (+10-12%) nicely ahead of expectations organically and leaves pathway to ...